Cambridge Quantum Announce Ph.D. Studentship to Develop Quantum Algorithms for Pharmaceutical Application
CAMBRIDGE, UNITED KINGDOM, October 20, 2020 – Cambridge Quantum Computing (CQC) is pleased to announce the opening of an exciting Ph.D. studentship with multinational pharmaceutical company, GSK and the University of Strathclyde to design and implement quantum algorithms for drug design and discovery.
The engagement will see the three parties combine their expertise in quantum chemistry and quantum computing (QC) to accelerate the development and adoption of QC based tools in early stage drug discovery, by presenting the opportunity for a highly unique, industry-based Ph.D. studentship.
CQC will provide access to both their EUMEN and t|ket⟩™ toolkits and to state-of-the-art quantum computing platforms – enabling the explicit treatment of electronic structures observed in transition states, reaction pathways and potential energy surfaces.
Applications for the Ph.D. studentship are invited and interested parties can apply at: https://uk.gsk.com/en-gb/careers/graduates/the-gsk-strathclyde-collaborative-phdprogramme/
Founded in 2014 and backed by some of the world’s leading quantum computing companies, CQC is a global leader in quantum software and quantum algorithms that
help clients get the best out of rapidly evolving quantum computing hardware. For more information, visit CQC at http://www.cambridgequantum.com.